<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307229</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-100643</org_study_id>
    <nct_id>NCT00307229</nct_id>
  </id_info>
  <brief_title>Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)</brief_title>
  <official_title>A Phase I Trial Investigating the Safety and Immunogenicity of an Adenovirus Encoding Rat HER-2 Administered Intradermally to Patients With Metastatic or Locally Recurrent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Breast Cancer Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine
      consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally
      recurrent breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>Weeks 4, 6, 7, 10, 14, 18, 22, 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumour response</measure>
    <time_frame>Weeks 6, 18</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adenoviral vector encoding rat Her-2/neu</intervention_name>
    <description>Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. metastatic or locally recurrent breast cancer,

          2. 18 years of age or older,

          3. Her-2/neu positive (3+ by immunohistochemistry or FISH +),

          4. One of the following

               1. currently receiving hormonal therapy or are candidates for such or,

               2. being considered for trastuzumab or,

               3. their cancer has progressed on trastuzumab

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Prior or concurrent malignancies except treated basal cell or squamous carcinoma of
             the skin or in situ cancer of the cervix or any other cancer treated and presumed
             cured more than five years prior to study entry.

          3. Currently receiving chemotherapy, immunotherapy, adenoviral gene therapy or biological
             cancer therapy. [Note: concurrent hormonal therapy (tamoxifen,aromatase inhibitors, or
             megace) is permitted.].

          4. Treatment with trastuzumab within 4 weeks prior to first dose of vaccine therapy.

          5. Hemoglobin &lt; 80 g/L or granulocytes &lt; 1.5 x 109 /L or lymphocytes &lt; 1.0 x 109 /L or
             platelets &lt; 100 x 109 /L.

          6. Baseline liver enzymes (AST or ALT) greater than 3 times upper limit of normal or
             greater than 5 times upper limit of normal if liver metastases present and/or
             bilirubin greater than 50 mmol.

          7. CD4 cells &lt; 0.5 x 109 /L

          8. Patients with documented brain metastases.

          9. Patients with any acute illness that would interfere with vaccination

         10. Any patients requiring concurrent immunosuppressive therapy (e.g. corticosteroids).

         11. Eastern Cooperative Oncology Group (ECOG) performance status of &gt; 2.

         12. Patients with a life expectancy of less than 6 months.

         13. Geographic inaccessibility which would preclude follow-up. Patients registered on the
             trial must be treated and followed at the Jewish General Hospital.

         14. Failure to give written informed consent.

         15. Baseline left ventricular ejection fraction (LVEF) &lt; 55% by echocardiography or MUGA
             scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerry Batist, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Lady Davis Institute for Medical Research Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronan Foley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2006</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

